Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody

Wu, Dong; Yin, Zhimin; Chen, Shanshan; He, Xiaowen; Li, Nan; Chen, Tao; Qiu, Hui; Zhao, Mengmeng; Zhou, Nina; Lu, Liqin; Tang, Dan-Li; Song, Jukun; Li, Huiping

doi:10.1080/10717544.2021.1921073

Cited by 7 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The particle size distribution of MPS-NSSLs was 95.4 ± 0.7 nm, the encapsulation rate of MPS reached 91.24 ± 0.27 %, and the drug-to-lipid ratio was about 0.4. The rat model experiments confirmed that MPS-NSSLs had specific targeting and good stability, which was consistent with the results of Weng et al (2021) (27). There are other reports (28)(29)(30)(31) in this regard.…”

Section: Discussionsupporting

confidence: 91%

Targeted Therapy of Tuberculous Meningitis in Rats with Methylprednisolone Composite Nanoparticles

Dai¹,

Guan²,

Qin³

2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Targeted Therapy of Tuberculous Meningitis in Rats with Methylprednisolone Composite Nanoparticles

Dai¹,

Guan²,

Qin³

2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

“…35 Because they possess many desirable attributes, such as small molecules, low immunogenicity, strong penetration, and high binding affinity, different types nanobodies have become novel diagnosis and treatment methods for tumors and infectious diseases. [36][37][38] We constructed a nanobody specific to dectin 1, which is an important PRR in fungal infection. We also verified that this nanobody can bind to the dectin 1 antigen and relieve the inflammatory response in fungal keratitis.…”

Section: Discussionmentioning

confidence: 99%

Preparation of a Nanobody Specific to Dectin 1 and Its Anti-inflammatory Effects on Fungal Keratitis

Liu¹,

Sui²,

Li³

et al. 2022

IJN

View full text Add to dashboard Cite

To prepare a nanobody specific to dectin 1 and verify its specificity and anti-inflammatory effects on Aspergillus fumigatus keratitis. Methods: The nanobody was selected from a high-quality shark-antibody library constructed with phage-display technology. The nanobody was developed in the expression systems of Escherichia coli. Indirect ELISA was used to determine the specificity of the nanobody to recombinant dectin 1 protein. The potential of the nanobody to be recognized and expressed on the surfaces of cells and corneas was detected by immunofluorescence, and its anti-inflammatory effect on A. fumigatus keratitis was further verified. After infection with A. fumigatus, eyes of C57B L/6 mice were treated with nanobodies. Human corneal epithelial cells (HCECs) were pretreated with nanobodies and then incubated with A. fumigatus. Clinical scores and slit-lamp photography were used to assess disease response in mouse corneas. RT-PCR and ELISA were used to evaluate mRNA and protein expression of IL1β and IL6 in both mouse corneas and HCECs. Results: The nanobody was successfully expressed through microbial system and showed specific high-affinity binding to recombinant dectin 1. Furthermore, it exhibited specific binding to dectin 1 expressed on the surfaces of cells and recognized dectin 1 in mouse corneas. Importantly, it reduced clinical scores of A. fumigatus keratitis in mice compared with a PBS-treatment group. In addition, it decreased mRNA and protein expression of IL1β and IL6 in infected corneas and HCECs stimulated with A. fumigatus. Conclusion: These results suggest that this nanobody can bring about anti-inflammatory effects. This highlights the potential of these nanobodies as innovative therapeutic agents in A. fumigatus.

show abstract

“…The presence of glucocorticoid-like methylprednisolone lowered the expression of NF-kappa B due to its anti-inflammatory properties in rats with bleomycin-induced ALI. Furthermore, this group also elucidated on the targetability of these NPs to specifically bind to human lung tissue but not to the human spleen, liver, and kidney tissues [ 86 ]. Wijagkanalan et al .…”

Section: Nanoparticles Targeting Macrophages For Ards/alimentioning

confidence: 99%

Macrophage-Targeted Nanomedicines for ARDS/ALI: Promise and Potential

Vichare

Janjić

2022

Inflammation

View full text Add to dashboard Cite

— Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are characterized by progressive lung impairment typically triggered by inflammatory processes. The mortality toll for ARDS/ALI yet remains high because of the poor prognosis, lack of disease-specific inflammation management therapies, and prolonged hospitalizations. The urgency for the development of new effective therapeutic strategies has become acutely evident for patients with coronavirus disease 2019 (COVID-19) who are highly susceptible to ARDS/ALI. We propose that the lack of target specificity in ARDS/ALI of current treatments is one of the reasons for poor patient outcomes. Unlike traditional therapeutics, nanomedicine offers precise drug targeting to inflamed tissues, the capacity to surmount pulmonary barriers, enhanced interactions with lung epithelium, and the potential to reduce off-target and systemic adverse effects. In this article, we focus on the key cellular drivers of inflammation in ARDS/ALI: macrophages. We propose that as macrophages are involved in the etiology of ARDS/ALI and regulate inflammatory cascades, they are a promising target for new therapeutic development. In this review, we offer a survey of multiple nanomedicines that are currently being investigated with promising macrophage targeting potential and strategies for pulmonary delivery. Specifically, we will focus on nanomedicines that have shown engagement with proinflammatory macrophage targets and have the potential to reduce inflammation and reverse tissue damage in ARDS/ALI. Graphical abstract

show abstract

Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody

Cited by 7 publications

References 32 publications

Targeted Therapy of Tuberculous Meningitis in Rats with Methylprednisolone Composite Nanoparticles

Targeted Therapy of Tuberculous Meningitis in Rats with Methylprednisolone Composite Nanoparticles

Preparation of a Nanobody Specific to Dectin 1 and Its Anti-inflammatory Effects on Fungal Keratitis

Macrophage-Targeted Nanomedicines for ARDS/ALI: Promise and Potential

Contact Info

Product

Resources

About